Welcome - Register - Login - Help/FAQ - 0 items

Search
Enter keywords, a title or
a report id number below.

Advanced


	Select a currency for use throughout the site

Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure

Electronic (PDF)
Site License
Enterprisewide

Live Chat Live Help Software for Website

Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment Landscape

GlobalData, March 2011, Pages: 6


	Description



		Table of Contents


		Enquire before Buying


		Send to a Friend

Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment Landscape

Summary

GlobalData’s report, “Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment Landscape” provides key information on current available treatment of Multiple Sclerosis, drivers and barriers for the future MS market and how the novel pipeline molecules will drive the global market

Scope

- Data and information on the impact of Gilenya (Fingolimod), Laquinimod and Cladribine on the current treatment landscape of Multiple Sclerosis

Reasons to buy

- Develop business strategies by understanding the trends and developments in Multiple Sclerosis market

For enquiries please call us on:

+353-1-415-1241 (GMT Office Hours)

1-800-526-8630 (US/Canada Toll Free)

1-917-300-0470 (EST Office Hours)